Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

被引：36
|
作者：
Kyriazanos, Ioannis [1 ]
Kalles, Vasileios [1 ]
Stefanopoulos, Anastasios [1 ]
Spiliotis, John [2 ]
Mohamed, Faheez [3 ]
机构：
[1] Naval & Vet Hosp Athens, Dept Surg 2, Athens, Greece
[2] Metaxa Canc Hosp, Dept Surg 1, Piraeus, Greece
[3] Hampshire Hosp NHS Fdn Trust, Basingstoke & North Hampshire Hosp, Peritoneal Malignancy Inst, Winchester, Hants, England
来源：
SURGICAL ONCOLOGY-OXFORD | 2016年 / 25卷 / 03期
关键词：
Peritoneal surface malignancy; Hyperthermic intraperitoneal chemotherapy; Operator safety; Cytoreductive surgery; Chemotherapy; HEALTH-CARE WORKERS; CYTOREDUCTIVE SURGERY; PERITONEAL CARCINOMATOSIS; EXPOSURE; CONTAMINATION; PENETRATION; SECONDARY; EFFICACY; CHEMOHYPERTHERMIA; OXALIPLATIN;
D O I：
10.1016/j.suronc.2016.06.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is increasingly used in the treatment of peritoneal malignancies. The administration of HIPEC after complete cytor-eduction offers the combination of the pharmacokinetic advantages inherent to the intraperitoneal delivery of cytotoxic chemotherapy, with the direct cytotoxic effects of hyperthermia, and has been reported to offer significantly improved patient outcomes. As a result, this novel method disseminates rapidly, with many surgical teams having developed peritoneal malignancy treatment programs. Protocols are needed for the introduction, handling, and management of chemotherapeutic agents in the operating room to minimize risk to the staff involved in the procedure. The personnel exposure during CRS and HIPEC may arise from different routes, such as air contamination, direct contact, manipulation of perfusates or chemotherapy solutions, and manipulation of objects/tissues exposed to chemotherapeutics. Guidelines for safe administration of HIPEC including environmental contamination risk management, personal protective equipment, and occupational health issues are yet to be established. This review summarizes the existing evidence regarding the safety considerations of HIPEC administration. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：308 / 314
页数：7
相关论文
共 50 条
  • [1] Safety considerations for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion
    Gonzalez-Bayon, L.
    Gonzalez-Moreno, S.
    Ortega-Perez, G.
    EJSO, 2006, 32 (06): : 619 - 624
  • [2] Hyperthermic intraperitoneal chemotherapy (HIPEC)
    Cervantes-Zamora, Antonio
    Sanchez-Prieto, Mario
    Felix-Guzman, Ulises
    Orozco-Orduna, Carlos U.
    Madrigal-Perez, Violeta M.
    GACETA MEXICANA DE ONCOLOGIA, 2022, 21 : 102 - 104
  • [3] Preventing Chemotherapy Exposure During Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    Flores, Susan
    WORKPLACE HEALTH & SAFETY, 2017, 65 (09) : 397 - 398
  • [4] Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel
    Simon, L.
    Halilou, M. -C.
    Gladieff, L.
    Gadiou, M.
    Herin, F.
    Hennebelle, I.
    Chatelut, E.
    Ferron, G.
    BULLETIN DU CANCER, 2009, 96 (10) : 971 - 977
  • [5] Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)
    Guerbet, M.
    Goulle, J. P.
    Lubrano, J.
    EJSO, 2007, 33 (05): : 623 - 626
  • [6] Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C
    Schmid, K.
    Boettcher, M. I.
    Pelz, J. O. W.
    Meyer, T.
    Korinth, G.
    Angerer, J.
    Drexler, H.
    EJSO, 2006, 32 (10): : 1222 - 1225
  • [7] HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) IN GYNECOLOGICAL MALIGNANCIES
    Friedrich, M.
    Altgassen, C.
    Terjung, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1492 - 1492
  • [8] HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) IN GYNECOLOGICAL MALIGNANCIES
    Friedrich, M.
    Zinn, W.
    Wullstein, C.
    Terjung, A.
    Altagssen, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1345 - 1345
  • [9] HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER
    van Driel, W. J.
    Koole, S.
    Sikorska, K.
    van Leeuwen, J. Schagen
    Schreuder, H. W.
    Hermans, R.
    de HIngh, I.
    van der Velden, J.
    Arts, H.
    Massuger, L.
    Aalbers, A.
    Verwaal, V.
    Kieffer, J.
    van der Vijver, K.
    van Tinteren, H.
    Aaronson, N.
    Sonke, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 2037 - 2037
  • [10] Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer
    Tsuyoshi, Hideaki
    Inoue, Daisuke
    Kurokawa, Tetsuji
    Yoshida, Yoshio
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2020, 46 (09) : 1661 - 1671
12345